Implantica Receives FDA Approval for RefluxStop Device
Implantica AG announced it has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its RefluxStop device. This approval grants the company access to the U.S. market.
Liechtenstein-based medtech company Implantica AG has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its RefluxStop device. This approval signifies a key milestone for the company's growth strategy, opening the door to the substantial U.S. market.
RefluxStop is a medical device designed to treat gastroesophageal reflux disease (GERD) without surgical intervention that alters the anatomy of the digestive system. The FDA's approval is based on clinical studies demonstrating the device's efficacy and safety in patients suffering from heartburn and acid regurgitation.
The approval is a significant step for Implantica, given the considerable market potential in the United States. GERD affects an estimated 20 percent of the Western population, and there is a clear demand for effective, less invasive treatment options.
Implantica plans to commence commercialization of the RefluxStop device in the U.S. shortly after the approval. The company anticipates the device will significantly improve the quality of life for GERD patients, offering a lasting solution to their symptoms without the need for long-term medication or surgery.